5th Annual ALS Research Symposium

DAY 2 (Friday, Oct. 7th):

MODERATOR: TBD

9:30 – 9:45am: Welcome & Introductions

9:45 – 10:45am: Industry Presentations

9:45-10:05am: AC Immune. Speaker: Tariq Afroz, PhD. 

• Abstract Title: “Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection through microglial engagement in mouse models of ALS/FTD”.

10:05am – 10:25am: Axoltis Pharma. Speaker: Sighild Lemarchant, PhD

• Abstract Title: “A multi-properties peptide (NX210c) for the treatment of ALS”.

10:25am – 10:45am: Biogen. Speaker: Michael Benatar, MD, PhD

• Abstract Title: “Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study.”

10:45 – 11:00: Break

11:00 – 12:00pm: Industry Presentations continued

11:00 – 11:20am: BrainEver. Speaker: Julien Spatazza, PhD.

• Abstract Title: “ENGRAILED-1 homeoprotein transcription factor as a novel therapeutic strategy for ALS.”

11:20 – 11:40am: Brainstorm-Cell Therapeutics. Speaker: Stacy Lindborg, PhD

• Abstract Title: “The Relationship Between CSF Biomarkers and Efficacy of Treatment with NurOwn (MSC-NTF).”

11:40 – 12:00pm: Eledon. Speaker: Steve Perrin, PhD

• Abstract title: “Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS.”

12:00 – 12:30: Lunch/Break

12:30 – 1:30pm: Industry Presentations continued.

MODERATOR: TBD

12:30 – 12:50pm: Ionis Pharmaceuticals. Speaker: Amy Shea  

• Abstract Title: “Ionis’ ALS Genetic Testing Program”.

12:50 – 1:10pm. NeuroSense. Speaker: Dr. Ferenc Tracik

• Abstract Title: “Shifting the Paradigm: PrimeC as a novel therapeutic strategy for ALS.”

1:10 – 1:30pm: QurAlis. Speaker: Angela Genge, MD

• Abstract Title: “QRL-201-01 – A multi-center, randomized, double-blind, placebo-controlled multiple‑ascending dose study to evaluate the safety and tolerability of QRL‑201 in amyotrophic lateral sclerosis”

1:30 – 1:45pm: Break

1:45 – 2:45pm: Industry Presentations continued.

1:45 – 2:05pm: SOLA Biosciences. Speaker: Akinori Hishiy, PhD

• Abstract Title: “Preclinical proof of concept of SOL-257, a gene therapy targeting misfolded TDP-43 in ALS.”

2:05 – 2:25pm: VectorY. Speaker: Marina Sogorb-Gonzáles

• Abstract Title: “Reduction of oxidized phospholipids or misfolded protein aggregates by AAV-VecTabs in an Amyotrophic Lateral Sclerosis pre-clinical models.”

2:25 – 2:45pm: Verge Genomics. Speaker: Irene Choi, PhD 

• Abstract Title: “Accelerating discovery and development of ALS therapeutics with an AI-powered All-in-Human Platform.”

2:45 – 3:00pm: Break

3:00 – 4:30pm Roundtable – panel discussion with speakers from day 1 and 2 – more info to come.